...Thank you, Chris. Good morning. I appreciate everyone taking the time to join us today. We provided several important business updates this morning in our press release and 10-K, including additional color on the FTX-6058 full clinical hold, data from the now suspended 12-milligram cohort of the Phase Ib sickle cell disease trial; updated guidance on our cash runway; and changes to our management team. Let me start by discussing our most recent updates to the FTX-6058 program, our oral HbF inducer for the potential treatment of patients with sickle cell disease. As we announced on February 24, we received verbal notification from the FDA on February 23, that they had placed a full clinical hold on the investigational new drug application for FTX-6058, and we received the formal clinical hold letter from the FDA on February 24. We immediately suspended dosing and paused enrollment in the Phase Ib trial. In its communication to us, the agency noted that the whole related to both preclinical...
